Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Focus on Pharmaceutical Care and Progress in Management of Patients with Liver Cirrhosis and Ascites

Progress on Diagnosis and Treatment of Refractoryascites in Patients with Hepatic Failure

Innovative approaches to the management of ascites in cirrhosis

Recent developments in the management of ascites in cirrhosis

Current management of refractory ascites in patients with cirrhosis

An update on the pathogenesis and clinical management of cirrhosis with refractory ascites

Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons

Optimal management of cirrhotic ascites: A review for internal medicine physicians

Management of refractory cirrhotic ascites: challenges and solutions

Nursing Experience of 61 Patients with Hepatic Cirrhosis Treated by Transfusion of Ultrafiltrated and Concentrated Self-Ascites

Drainage of ascites in cirrhosis

Review article: Recent advances in ascites and acute kidney injury management in cirrhosis

Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis

Chinese guidelines on the management of ascites and its related complications in cirrhosis

Ascites, refractory ascites and hyponatremia in cirrhosis

Novel Innovations in Ascites Management

The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis

Fluid and electrolyte management of ascites in patients with cirrhosis

The management and nursing care of cirrhotic ascites

Current and future pharmacological therapies for managing cirrhosis and its complications

The portal hypertension syndrome: etiology, classification, relevance, and animal models